FGFR4 and colorectal carcinoma: Additionally, in CRC organoids, significant growth reduction has been observed in both FGFR4-variant and wild-type CRC organoids, attributed to FGFR4-targeted drugs, such as erdafitinib and FGFR4-IN-1, suggesting that these inhibitors may lack selectivity for FGFR4 genotypes 258.